

NEWS RELEASE

FOR IMMEDIATE RELEASE
Tuesday, October 12, 2010

FOR FURTHER INFORMATION
Contact: info@czbiomed.com

CZ BIOMED CORP. RESEARCH FOR CANCER CURE – RVLYSIN®

Carson City, NV and Tampa, FL...**CZ BioMed Corp.** is a privately held Biotechnology company focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers.

RVLYSIN® is the invention of **CZ BioMed Corp.** RVLYSIN® is a novel oncolytic virus that selectively kills tumor cells, but does not kill off the normal or good cells within the body. RVLYSIN® is vastly safer to use as compared to traditional chemo – or radio-therapy of tumors, with a much higher quality of life during treatment.

This new product is well-tolerated in all experimental mice to date. RVLYSIN® specifically localizes to the tumor upon administration, and does not spread to other tissues or organs. Thus, this procedure is not harming areas of the body that are not currently in danger of the cancer.

During this process, the primary replication of oncolytic viruses within the cancer cells will directly kill the targeted tumor cells. The resultant explosion of the cancer cell activates a cascade of anti-tumor immune responses including interferon release. These payloads act in concert with the primary oncolysis mechanism to eradicate the cancer.

There are currently more than 100 different types of cancer. Even though there have been many advancements for the cure, there are still terrifying projected numbers. *An estimated 569,490 people will die from cancer in the United States in 2009 alone. As a specific example, an estimated 192,370 patients were newly diagnosed with breast cancer in the United States in 2009, and about 40,170 died of the disease. Although advancements in the treatment of breast cancer have lead to an improvement in outcomes, the 5-year survival rates for those diagnosed with regional and metastatic diseases are 80% and 26% respectively. Approximately 24% to 30% of women who have no lymph-node involvement at the time of diagnosis will relapse; and the relapse rate for node-positive women is 50% - 60%. Therefore, a safe and effective treatment remains a critical need.

One of our products, **BRVLYSIN** was found to effectively kill different types of breast cancer cells. Also, **BRVLYSIN** induces tumor growth regression in vivo, indicating that **BRVLYSIN** functions as a novel biodrug fighting against breast cancer.

“We are very excited to reach this milestone today. Our hard work and dedication to cure cancer is another step closer. This breakthrough will allow patients to recover faster, will not destroy the healthy cells and is the next step to the cure of this deadly disease. We hope that in the future our finding will join the elite class of cancer drugs developed by Roche (RHHBY.pk); Eli Lilly (NYSE:LLY); Amgen Inc. (NASD:AMGN); Dendreon Corp. (NASD: DNDN); Genzyme Corp. (NASD: GENZ) and many other companies in this relentless pursuit to fight against cancer.” stated Calvin Cao, Chairman/CEO/President of CZ BioMed Corp.

This project is ready to go to *Phase 1* of clinical trial studies. We currently have four (4) patents pending on these key technologies. With that in place, the company is entering a critical period and we are presently looking for key partners to take this project to the next level. We believe we could transform the traditional biological drug development process utilizing a lean approach to generating clinical proof- of -concept (POC) data and a 100% outsourcing model.

The mission of **CZ BioMed Corp.** is rooted in the knowledge of our invention and the products we provide affect the quality of patients' lives. Since everything we do, no matter how small, impacts the end product. We demand the highest ethical and quality standards, both from ourselves and others.

*(<http://www.cancer.gov/cancertopics/what-is-cancer>)

Calvin Cao:

Mr. Cao is the founder of CZ BioMed Corp. As an inventor, innovator and bio-entrepreneur, his strategy and commitment is to make CZ Biomed the dominant global company for the discovery and development of a new class of high-tech biological products for the treatment of a wide variety of human cancers.

In 2008, as a chairman and co-founder of Stem Cell Therapy International Corp. he engineered the recent merger of Stem Cell Therapy International and Histostem of S. Korea. Histostem is one of the largest fully accredited cord blood banks in the world, with more than 80,000 cord blood units for use in research and treatments. The successful merger has formed one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity Amstem Corp.

About CZ BioMed Corp

CZ BioMed Corp. is a privately held Biotechnology company focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. The Company applies its expertise in genetically engineered Oncolytic virus RVLYSIN® that selectively kills tumor cells, but does not kill off the normal or good cells within the body. Using oncolytic virotherapy to targeting, attacking and eradicating the tumor cells. For further information about CZ BioMed Corp. please visit: www.czbiomed.com

Forward Looking Statements

This report includes "*forward-looking statements*" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and general economic risks and uncertainties.

